The Effect of Soy Isoflavones on the Menopause Rating Scale Scoring in Perimenopausal and Postmenopausal Women: A Pilot Study
Introduction: Menopause is associated with many unpleasant symptoms which vary in different phases of menopausal transition. Although, Hormone Replacement Therapy (HRT) is considered the most effective mode of treatment for these symptoms, its use is associated with increased risk of breast canc...
| Published in: | Journal of Clinical and Diagnostic Research |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2017-09-01
|
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/10654/26034_CE(RA1)_F(T)PF1-(MJ_PY)_PFA(VJ_SS).pdf |
| Summary: | Introduction: Menopause is associated with many unpleasant
symptoms which vary in different phases of menopausal transition.
Although, Hormone Replacement Therapy (HRT) is considered
the most effective mode of treatment for these symptoms, its use
is associated with increased risk of breast cancer, endometrial
cancer and thromboembolic events. Soy isoflavones are being
widely used as a safer alternative to HRT, even though scientific
evidence of their efficacy is poor or lacking.
Aim: To study the effect of soy isoflavone supplementation on the
menopausal symptoms in perimenopausal and postmenopausal
women.
Materials and Methods: An observational pilot study was done
involving 29 perimenopausal and 21 postmenopausal women
prescribed 100 mg soy isoflavones for 12 weeks. Menopause
Rating Scale (MRS) questionnaire was administered to the
patients before starting soy isoflavone therapy and at the end of
treatment. Responses were analysed using Statistical Package
for Social Sciences (SPSS) software 23.0.
Results: Total score of both the groups were comparable at
baseline. Among perimenopausal women highest score was given
to symptoms of psychological domain. Urogenital symptoms
were the worst among postmenopausal women. After 12 weeks
of treatment, total scores improved significantly by 19.55% and
12.62% in the perimenopausal and postmenopausal women
respectively. The greatest improvement was seen in scores of
hot flashes for both the groups and the least improvement was
shown by symptoms of urogenital subscale.
Conclusion: Soy isoflavone improves the MRS score among
both the perimenopausal and postmenopausal women. As they
are most effective for somatic and psychological symptoms,
their use could be beneficial during perimenopause. |
|---|---|
| ISSN: | 2249-782X 0973-709X |